๊ฐ„๊ฒฝ๋ณ€ ๋™๋ฐ˜ ์ƒ๋ถ€์œ„์žฅ๊ด€ ์ถœํ˜ˆ ํ•ญ์ƒ์ œ ์˜ˆ๋ฐฉ / Antibiotic prophylaxis in cirrhotic upper GI bleeding

์ •์˜

๊ฐ„๊ฒฝ๋ณ€ ๋˜๋Š” ๋ฌธ๋งฅ๊ณ ํ˜ˆ์•• ๋ฐฐ๊ฒฝ์—์„œ hematemesis/melena ๋“ฑ ์ƒ๋ถ€์œ„์žฅ๊ด€ ์ถœํ˜ˆ์ด ์˜์‹ฌ๋  ๋•Œ, ์ถœํ˜ˆ์›์ด ์ •๋งฅ๋ฅ˜๋กœ ํ™•์ •๋˜์ง€ ์•Š์•„๋„ ๊ฐ์—ผ ์˜ˆ๋ฐฉ ๋ชฉ์ ์˜ ํ•ญ์ƒ์ œ๋ฅผ ์กฐ๊ธฐ ํˆฌ์—ฌํ•˜๋Š” ์ ‘๊ทผ์ด๋‹ค.

์ž„์ƒ ํ•ต์‹ฌ

LC stigmata, ascites, known cirrhosis, thrombocytopenia/splenomegaly ๋“ฑ์ด ์žˆ์œผ๋ฉด โ€œcirrhotic UGIBโ€๋กœ ๊ฐ„์ฃผํ•œ๋‹ค. ์ด ๊ฒฝ์šฐ blood culture๋ฅผ ํ•ญ์ƒ์ œ ์ „ ํ•„์ˆ˜ ์ ˆ์ฐจ๋กœ ๋‘์–ด ํˆฌ์•ฝ์„ ์ง€์—ฐ์‹œํ‚ค์ง€ ์•Š๋Š”๋‹ค. ๊ฐ์—ผ ์˜ˆ๋ฐฉ ํ•ญ์ƒ์ œ๋Š” bacterial infection, rebleeding, mortality ๊ฐ์†Œ์™€ ๊ด€๋ จ๋œ๋‹ค.

์ง„๋‹จ

์ถœํ˜ˆ ์–‘์ƒ๊ณผ ๊ฐ„๊ฒฝ๋ณ€/๋ฌธ๋งฅ๊ณ ํ˜ˆ์•• ๋‹จ์„œ๋ฅผ ๋™์‹œ์— ํ‰๊ฐ€ํ•œ๋‹ค. Fever, leukocytosis, shock out of proportion, suspected sepsis, SBP ๊ฐ€๋Šฅ ascites๊ฐ€ ์žˆ์œผ๋ฉด blood culture 2์Œ๊ณผ ascitic fluid culture๋ฅผ ๊ฐ€๋Šฅํ•œ ํ•œ ๋นจ๋ฆฌ ์ฑ„์ทจํ•œ๋‹ค.

์น˜๋ฃŒ

๊ฐ„๊ฒฝ๋ณ€/๋ฌธ๋งฅ๊ณ ํ˜ˆ์•• ํ™˜์ž์˜ UGIB ์˜์‹ฌ ์‹œ culture ๊ฒฐ๊ณผ๋ฅผ ๊ธฐ๋‹ค๋ฆฌ์ง€ ๋ง๊ณ  ํ•ญ์ƒ์ œ prophylaxis๋ฅผ ์‹œ์ž‘ํ•œ๋‹ค. ์‹ค๋ฌด ์˜ˆ๋กœ ceftriaxone์„ ์‚ฌ์šฉํ•˜๋ฉฐ, culture ์ฑ„์ทจ๊ฐ€ ํ•„์š”ํ•ด๋„ ํ•ญ์ƒ์ œ ํˆฌ์—ฌ๋ฅผ ์ง€์—ฐํ•˜์ง€ ์•Š๋Š”๋‹ค.

์ถœ์ฒ˜

Baveno VII consensus portal hypertension; ESGE 2022 esophagogastric variceal hemorrhage guideline.

๐ŸŒฑ ์ถœ์ฒ˜ raw


๋ณธ ๋ฌธ์„œ๋Š” ํ•™์Šตยท์ฐธ๊ณ ์šฉ์ด๋ฉฐ ์‹ค์ œ ์ง„๋ฃŒ ๊ฒฐ์ •์€ ์ž„์ƒ์˜์˜ ํŒ๋‹จ์ž…๋‹ˆ๋‹ค.